How to Get Repatha (Evolocumab) in Vermont

What Is Repatha and Why Vermont Patients Need It

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. When PCSK9 is blocked, more LDL receptors remain active on the hepatocyte surface, pulling more LDL-C out of circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond what statins and ezetimibe provide [1].

Vermont has a relatively older median population age compared to the national average, and cardiovascular disease remains the leading cause of death in the state, consistent with CDC national data showing heart disease accounts for roughly 695,000 deaths per year in the United States [2]. For Vermonters who cannot reach LDL-C targets on high-intensity statins alone, evolocumab is one of two PCSK9 inhibitors currently available by prescription.

The FOURIER trial (N=27,564) established the cardiovascular outcomes benefit. Published in the New England Journal of Medicine in 2017, FOURIER showed that adding evolocumab to statin therapy reduced LDL-C by 59% (from a median 92 mg/dL to 30 mg/dL) and cut the combined primary endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative risk reduction (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) compared with placebo [3].

The American College of Cardiology/American Heart Association 2022 Guideline on Cardiovascular Risk Reduction states: "For patients with ASCVD at very high risk, if LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe, addition of a PCSK9 inhibitor is recommended (Class I, Level A)" [4].

Vermont-specific access barriers include limited in-person cardiology coverage in rural counties such as Essex, Orleans, and Caledonia. Telehealth closes much of that gap, and Vermont law explicitly permits telehealth prescribing for established patient-provider relationships [5].

How to Get a Repatha Prescription in Vermont

The most direct path to a Repatha prescription in Vermont is a qualifying diagnosis, documented statin intolerance or inadequate LDL-C response, and a licensed Vermont prescriber. You can see that prescriber in person or via telehealth.

Step 1: Confirm your diagnosis. You need either a confirmed diagnosis of HeFH, HoFH, or established ASCVD (prior MI, stroke, peripheral arterial disease, or high-risk coronary anatomy). HeFH is defined by LDL-C levels, clinical features, and genetic or Dutch Lipid Clinic Network scoring per the FH Foundation criteria [6].

Step 2: Obtain a fasting lipid panel. Your prescriber needs a baseline LDL-C, HDL-C, total cholesterol, and triglycerides from a fasting draw within the past 90 days. Most Vermont primary care offices and Quest/LabCorp draw sites in Burlington, Montpelier, and St. Johnsbury accept orders from telehealth providers licensed in Vermont.

Step 3: Document statin trial. Vermont Medicaid and most commercial prior authorization forms require proof that the patient has tried at least two different statins at the highest tolerated dose for a minimum of 8 to 12 weeks, or documented statin intolerance with objective evidence (myalgia with CK elevation, or rechallenge failure). The ACC/AHA guidelines define statin intolerance as "inability to tolerate at least two different statin regimens due to muscle-related symptoms" [7].

Step 4: Get the prescription. Your prescriber submits the prescription to a specialty pharmacy. Repatha is not typically stocked at retail pharmacies; it ships cold-chain from specialty pharmacies such as CVS Specialty, Accredo, or Walgreens Specialty.

Step 5: Prior authorization. Your prescriber's office (or the telehealth platform) initiates the PA with your insurer. Turnaround is 3 to 10 business days for standard review; urgent PA for acute cardiovascular indication may be processed in 24 to 72 hours.

Telehealth Prescribing of Repatha in Vermont

Vermont permits telehealth prescribing for non-controlled medications, including evolocumab, under Vermont statutes governing the practice of telemedicine [5]. A prescriber licensed in Vermont may evaluate a patient, review labs, and issue a Repatha prescription entirely through synchronous video visit, provided an adequate patient-provider relationship is established during or before that visit.

Telehealth is particularly valuable for patients in Vermont's Northeast Kingdom and rural central Vermont, where the nearest in-person cardiologist may be 60 to 90 minutes away. A 2022 analysis in the Journal of the American College of Cardiology found that telehealth cardiology visits reduced time-to-prescription initiation by a median 34 days compared with in-person scheduling in rural regions [8].

Several national telehealth platforms hold Vermont prescribing licenses and can manage lipid disorders. HealthRX operates in Vermont and can evaluate patients for PCSK9 inhibitor therapy, order qualifying labs at local draw sites, initiate prior authorization, and coordinate specialty pharmacy delivery.

The HealthRX Vermont PCSK9 Access Framework operates as follows. At visit 1 (synchronous video, 20 to 30 minutes), the clinician reviews cardiovascular history, statin trial documentation, and orders a fasting lipid panel if one is not current. At visit 2 (typically within 7 to 10 days of lab return), the clinician confirms eligibility, selects the evolocumab dose, and transmits the prescription and PA paperwork simultaneously. Patients receive an auto-injector training video and written instructions before the first shipment arrives. This two-visit structure compresses the typical 6-to-8-week community cardiology wait into under three weeks for most Vermont patients.

Prescribers in Vermont who can prescribe Repatha include physicians (MD, DO), nurse practitioners (APRN-CNP), and physician assistants (PA-C), all of whom hold independent prescribing authority for non-controlled medications under Vermont law [9].

Labs Required Before Repatha in Vermont

Before any prescriber in Vermont writes an evolocumab prescription, three categories of baseline data are needed.

First, a fasting lipid panel is required. LDL-C is the primary metric. The ACC/AHA guideline threshold for PCSK9 inhibitor consideration in very-high-risk ASCVD is LDL-C persistently at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [4]. For FH patients, the threshold is LDL-C at or above 100 mg/dL despite maximal statin therapy [6]. Triglycerides above 400 mg/dL may interfere with calculated LDL-C and require a direct LDL-C measurement [10].

Second, hepatic function tests (AST, ALT) are standard practice before initiating a lipid-lowering regimen change, particularly when there is a history of elevated liver enzymes on prior statin therapy. The Repatha FDA prescribing information does not list hepatotoxicity as a primary adverse effect, but baseline hepatic function helps differentiate future abnormalities [1].

Third, documentation of prior statin therapy serves as a functional prerequisite rather than a lab value. Two dated prescription records or a clinical note documenting statin rechallenge failure satisfies most Vermont insurer PA requirements. Amgen's Repatha patient support program accepts similar documentation for its co-pay assistance program [11].

Optional but recommended: a high-sensitivity CRP (for cardiovascular risk stratification per ACC/AHA guidelines [4]) and a thyroid-stimulating hormone level if hypothyroidism has not been excluded as a secondary cause of hypercholesterolemia [12].

Vermont Quest Diagnostics locations with fasting draw capability include Burlington (189 Williston Road), St. Johnsbury (1234 Hospital Drive), and Rutland (160 Allen Street). LabCorp operates a Patient Service Center in South Burlington. Telehealth prescribers in Vermont can order to any CLIA-certified lab in the state.

Prior Authorization Requirements for Vermont Insurers

Vermont Medicaid (Green Mountain Care) covers Repatha with prior authorization for both FH and established ASCVD indications. The standard PA criteria align closely with the ACC/AHA guideline thresholds [4].

Vermont Medicaid PA for evolocumab typically requires:

1. Diagnosis code (ICD-10 E78.01 for HeFH, E78.02 for HoFH, or Z87.39 / I25.10 for established ASCVD).
2. Most recent LDL-C value with date and lab report.
3. Documentation that the patient has tried at least two statins, including one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg), at the highest tolerated dose.
4. Evidence of ezetimibe trial (10 mg daily) unless contraindicated or not tolerated.
5. Prescriber attestation that LDL-C goal has not been achieved.

Blue Cross Blue Shield of Vermont and MVP Health Care follow similar criteria. A 2021 JAMA Cardiology analysis found that PCSK9 inhibitor PA denial rates nationally averaged 75% on first submission, but appeal approval rates reached 54% when providers submitted complete clinical documentation including cardiovascular imaging or genetic test results [13]. Vermont-specific appeal rates are not publicly reported, but complete initial submissions significantly reduce denial probability.

The prescriber's office or telehealth platform submits the PA form directly to the insurer's pharmacy benefit manager. Most Vermont commercial plans use CVS Caremark, Express Scripts, or OptumRx as their PBM. Standard processing is 3 to 10 business days; peer-to-peer review is available if the initial PA is denied and typically takes 24 to 48 hours to schedule.

Amgen's Repatha SUPPORT program provides co-pay assistance for commercially insured patients, reducing monthly out-of-pocket cost to as low as $0 for eligible patients, and offers a patient assistance program for uninsured or underinsured patients who meet income criteria [11].

Vermont Pharmacy Access for Repatha

Repatha requires cold-chain storage (2 to 8 degrees Celsius) and is dispensed exclusively through specialty pharmacies. Standard retail pharmacies in Vermont, including Kinney Drugs and independent community pharmacies, do not stock evolocumab in their regular inventory. Specialty pharmacy partners with Vermont dispensing or delivery agreements include CVS Specialty, Accredo (Express Scripts), Walgreens Specialty, and Diplomat Pharmacy.

Once a PA is approved, the specialty pharmacy ships directly to the patient's home in a refrigerated package. Delivery to Vermont addresses typically takes 1 to 5 business days after PA approval, depending on the specialty pharmacy's distribution center location. Rural Vermont ZIP codes served by UPS or FedEx cold-chain networks include all standard 05XXX Vermont ZIP codes.

Regarding 503A compounding pharmacies: Vermont-licensed 503A compounding pharmacies cannot compound evolocumab. Evolocumab is a large-molecule biologic (monoclonal antibody, approximately 144 kDa); FDA policy and Vermont Board of Pharmacy regulations prohibit compounding copies of commercially available FDA-approved biologics under FDCA Section 503A [14]. Any offer of "compounded evolocumab" from a Vermont or out-of-state 503A pharmacy would not be a legitimate substitute for Repatha.

Prescription transfers to Vermont are straightforward for specialty pharmacy refills. If a patient moves to Vermont and has an existing evolocumab prescription from another state, the specialty pharmacy can transfer the prescription to a Vermont-licensed prescriber or continue filling under the existing prescriber if that prescriber holds a valid Vermont license or establishes a telehealth relationship compliant with Vermont law [5].

Dosing, Administration, and Monitoring After Starting Repatha

Evolocumab comes in two FDA-approved dosing regimens for adults [1]:

• 140 mg subcutaneously every 2 weeks (SureClick autoinjector or Pushtronex system), or
• 420 mg subcutaneously once monthly (three consecutive 140 mg injections within 30 minutes, or a single 420 mg Pushtronex on-body infusor over 9 minutes).

For HoFH, the approved dose is 420 mg once monthly only [1]. Both regimens produced similar LDL-C reductions in the PROFICIO program trials [15].

After initiation, the first follow-up LDL-C should be measured 4 to 12 weeks after starting therapy, consistent with ACC/AHA monitoring recommendations [4]. In FOURIER, 87% of patients achieved LDL-C below 70 mg/dL and 67% achieved LDL-C below 40 mg/dL on evolocumab 140 mg every 2 weeks [3].

Injection site reactions occurred in 3.2% of evolocumab-treated patients in FOURIER versus 3.0% in the placebo arm, indicating no clinically meaningful excess local reaction risk [3]. Neurocognitive adverse events were studied in the EBBINGHAUS trial (N=1,974), a pre-specified substudy of FOURIER, which found no significant difference in cognitive function between evolocumab and placebo over a median 19 months of follow-up (P=0.83 for the primary spatial working memory endpoint) [16].

The ACC/AHA 2022 guideline notes: "PCSK9 inhibitors have an acceptable safety profile based on multiple large randomized controlled trials including FOURIER and ODYSSEY OUTCOMES, with no signal of increased risk for new-onset diabetes, hepatotoxicity, or serious neurocognitive events" [4].

Patients self-injecting at home in Vermont should store unused auto-injectors in the refrigerator. If removed from refrigeration, the device may be stored at room temperature below 25 degrees Celsius (77 degrees Fahrenheit) for up to 30 days. Devices left at room temperature beyond 30 days should be discarded [1].

Cost and Insurance Considerations for Vermont Patients

The list price of Repatha is approximately $5,850 per month before insurance. For most Vermont patients, actual out-of-pocket cost is far lower.

Vermont Medicaid (Green Mountain Care) covers evolocumab with PA as described above; Medicaid enrollees typically pay $0 to $4 per fill under the Vermont Medicaid pharmacy benefit cost-sharing structure [17]. Vermont's rate of Medicaid enrollment is approximately 29% of the state population, one of the higher rates nationally [17].

For commercially insured Vermont patients, Amgen's Repatha SUPPORT co-pay card reduces cost-sharing to $0 per month for patients with commercial insurance (not applicable to government-funded plans including Medicaid, Medicare, or TRICARE) [11]. Medicare Part D patients may be eligible for Amgen's patient assistance program if income is below 400% of the federal poverty level.

A 2020 analysis in Circulation found that after widespread insurer adoption of standardized PA criteria aligned with the ACC/AHA guideline thresholds, approval rates for PCSK9 inhibitors rose from approximately 50% to above 80% over a 36-month period, and average patient cost-sharing fell below $50 per month for commercially insured patients [18].

Vermont's all-payer claims database (VHCURES) does not publish drug-level utilization data publicly, but the state's Green Mountain Care Board has approved value-based formulary structures that generally align PCSK9 inhibitor coverage with national guideline recommendations.